4//SEC Filing
Arkin Moshe 4
Accession 0001178913-20-001105
CIK 0001664710other
Filed
Apr 12, 8:00 PM ET
Accepted
Apr 13, 5:29 PM ET
Size
19.8 KB
Accession
0001178913-20-001105
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2020-04-13+1,382,295→ 1,382,295 total - Purchase
Common Stock
2020-04-13$16.00/sh+120,000$1,920,000→ 2,013,102 total - Conversion
Series B-1 Preferred Stock
2020-04-13−343,270→ 0 total→ Common Stock (343,270 underlying) - Conversion
Series C Preferred Stock
2020-04-13−167,537→ 0 total→ Common Stock (167,537 underlying) - Conversion
Common Stock
2020-04-13+167,537→ 1,893,102 total - Conversion
Common Stock
2020-04-13+343,270→ 1,725,565 total - Conversion
Series A Preferred Stock
2020-04-13−1,382,295→ 0 total→ Common Stock (1,382,295 underlying)
Arkin Moshe
10% Owner
Transactions
- Conversion
Common Stock
2020-04-13+1,382,295→ 1,382,295 total - Purchase
Common Stock
2020-04-13$16.00/sh+120,000$1,920,000→ 2,013,102 total - Conversion
Common Stock
2020-04-13+343,270→ 1,725,565 total - Conversion
Series A Preferred Stock
2020-04-13−1,382,295→ 0 total→ Common Stock (1,382,295 underlying) - Conversion
Series B-1 Preferred Stock
2020-04-13−343,270→ 0 total→ Common Stock (343,270 underlying) - Conversion
Common Stock
2020-04-13+167,537→ 1,893,102 total - Conversion
Series C Preferred Stock
2020-04-13−167,537→ 0 total→ Common Stock (167,537 underlying)
Arkin Bio Venture Partners Ltd.
10% Owner
Transactions
- Conversion
Common Stock
2020-04-13+1,382,295→ 1,382,295 total - Conversion
Common Stock
2020-04-13+343,270→ 1,725,565 total - Conversion
Common Stock
2020-04-13+167,537→ 1,893,102 total - Purchase
Common Stock
2020-04-13$16.00/sh+120,000$1,920,000→ 2,013,102 total - Conversion
Series A Preferred Stock
2020-04-13−1,382,295→ 0 total→ Common Stock (1,382,295 underlying) - Conversion
Series B-1 Preferred Stock
2020-04-13−343,270→ 0 total→ Common Stock (343,270 underlying) - Conversion
Series C Preferred Stock
2020-04-13−167,537→ 0 total→ Common Stock (167,537 underlying)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.
- [F2]The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd..
Documents
Issuer
Keros Therapeutics, Inc.
CIK 0001664710
Entity typeother
Related Parties
1- filerCIK 0001321178
Filing Metadata
- Form type
- 4
- Filed
- Apr 12, 8:00 PM ET
- Accepted
- Apr 13, 5:29 PM ET
- Size
- 19.8 KB